The treatment achieved a 72% objective response rate in patients with previously treated germline BRCA1/2-mutated advanced ovarian cancer.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.